Colinz Labs

{
  "main_header": {
    "sid": 621096,
    "name": "Colinz Labs",
    "stock_name": "Colinz Labs",
    "full_name": "Colinz Laboratories Ltd",
    "name_url": "stocks-analysis/colinz-labs",
    "exchange": 0,
    "exchangecode": "",
    "country_id": 34,
    "currency": "INR",
    "cmp": "76.02",
    "chg": -4,
    "chgp": "-5.0%",
    "dir": -1,
    "prev_price": "80.02",
    "mcapval": "19.00 Cr",
    "mcap": "Micro Cap",
    "scripcode": 531210,
    "symbol": "",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 4,
    "indexname": "",
    "isin": "INE923C01011",
    "curr_date": "Feb 02",
    "curr_time": "",
    "bse_nse_vol": "635 ",
    "exc_status": "Active",
    "traded_date": "Feb 02, 2026",
    "traded_date_str": "2026 02 02",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-registerF-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/colinz-labs-621096-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Colinz Laboratories Ltd Forms Golden Cross, Signalling Potential Bullish Breakout",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/colinz-laboratories-ltd-forms-golden-cross-signalling-potential-bullish-breakout-3808158",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/1/ColinzLaborator_goldencross_3808158.png",
        "date": "2026-01-28 18:00:15",
        "description": "Colinz Laboratories Ltd has recently formed a Golden Cross, a significant technical indicator where the 50-day moving average (DMA) has crossed above the 200-day moving average. This development often signals a potential bullish breakout, indicating a possible trend reversal and a shift towards long-term upward momentum for the pharmaceutical and biotechnology company."
      },
      {
        "title": "Are Colinz Laboratories Ltd latest results good or bad?",
        "link": "https://www.marketsmojo.com/news/result-analysis/are-colinz-laboratories-ltd-latest-results-good-or-bad-3804346",
        "imagepath": "",
        "date": "2026-01-25 19:11:24",
        "description": "Colinz Laboratories Ltd's latest financial results for Q3 FY26 reveal a complex operational landscape characterized by contrasting trends in revenue and profitability. The company reported net sales of ₹1.43 crores, reflecting a quarter-on-quarter increase of 2.88%. However, this modest growth is overshadowed by a significant decline in net profit, which fell to ₹0.08 crores, representing a 42.86% decrease from the previous quarter. \n\nThe profit after tax (PAT) margin also saw a notable contraction, dropping to 5.59% from 10.07% in the prior quarter, indicating challenges in maintaining operational efficiency and cost management. While the operating margin improved slightly to 6.99%, it remains below previous levels, highlighting ongoing issues with profitability.\n\nYear-on-year comparisons further illustrate the company's struggles, as revenue decreased by 2.72% from ₹1.47 crores in Q3 FY25. This trend of d..."
      },
      {
        "title": "Colinz Laboratories Q3 FY26: Marginal Revenue Growth Masks Deeper Profitability Concerns",
        "link": "https://www.marketsmojo.com/news/result-analysis/colinz-laboratories-q3-fy26-marginal-revenue-growth-masks-deeper-profitability-concerns-3803825",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/1/ColinzLaborator_quaterlyResult_3803825.png",
        "date": "2026-01-24 21:31:19",
        "description": "Colinz Laboratories Ltd., a micro-cap pharmaceutical formulations manufacturer, reported a modest quarterly performance for Q3 FY26, with net profit declining 42.86% quarter-on-quarter to ₹0.08 crores from ₹0.14 crores in Q2 FY26. On a year-on-year basis, net profit increased 60.00% from ₹0.05 crores in Q3 FY25, though this comparison benefits from an exceptionally weak base quarter. With a market capitalisation of just ₹13.00 crores, the Mumbai-based company continues to struggle with scale and profitability consistency, as reflected in its current stock price of ₹46.20, down 47.91% from its 52-week high of ₹88.70."
      },
      {
        "title": "Colinz Laboratories Ltd is Rated Strong Sell",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/colinz-laboratories-ltd-is-rated-strong-sell-3771259",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/12/ColinzLaborator_mojoScore_3771259.png",
        "date": "2025-12-26 15:12:03",
        "description": "Colinz Laboratories Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 11 June 2025. However, the analysis and financial metrics presented here reflect the stock's current position as of 26 December 2025, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook."
      },
      {
        "title": "Why is Colinz Labs falling/rising?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/why-is-colinz-labs-fallingrising-3764224",
        "imagepath": "",
        "date": "2025-12-20 02:14:07",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n\n<p><strong>Recent Price Movement and Volatility</strong></p>\n<p>Colinz Laboratories has experienced a notable downturn over the past three days, with cumulative losses amounting to 11.44%. The stock opened sharply lower on 19-Dec, down 2%, and reached an intraday low of ₹44.41, representing a 14.6% decline from previous levels. Trading activity was marked by high volatility, with an intraday price range of ₹7.59 and a volatility measure of 7.86% based on weighted average price. Despite this, the weighted average price indicated that most volume was transacted near the lower end of the day’s range, signalling selling pressure.</p>\n<p>Technical indicators reveal a mixed picture. The stock price remains above its 20-day, 50-day, and 100-day moving averages, suggesting some underlying support. However, it ..."
      },
      {
        "title": "Colinz Labs Sees Revision in Market Evaluation Amidst Challenging Financial Trends",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/colinz-labs-downgraded-to-strong-sell-amid-weak-fundamentals-and-valuation-concerns-3753349",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/12/ColinzLabs_mojoScore_3753349.png",
        "date": "2025-12-09 10:10:07",
        "description": "Colinz Labs, a microcap player in the Pharmaceuticals & Biotechnology sector, has experienced a revision in its market evaluation reflecting ongoing challenges in its financial and operational metrics. This development highlights shifts in the company’s quality, valuation, financial trends, and technical outlook, providing investors with a clearer understanding of its current standing within a competitive industry."
      },
      {
        "title": "Why is Colinz Labs falling/rising?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/why-is-colinz-labs-fallingrising-3702316",
        "imagepath": "",
        "date": "2025-11-14 21:44:17",
        "description": "As of 14-Nov, Colinz Laboratories Ltd is experiencing a price increase, currently at 42.74, which reflects a rise of 0.94 or 2.25%. The stock has shown strong performance recently, gaining for four consecutive days and achieving a total return of 7.49% during this period. Additionally, it has outperformed its sector by 1.88%. In terms of returns compared to the benchmark, over the past week, the stock has increased by 2.91%, while the Sensex has risen by 1.62%. The stock's delivery volume has also seen a significant increase of 48.13% compared to the five-day average, indicating rising investor participation. However, it is important to note that there is no information available regarding any positive or negative factors that could further explain the stock's recent movement.\n\nBroader Market Context: In the short term, Colinz Laboratories Ltd has outperformed the Sensex, which suggests that investor sentim..."
      },
      {
        "title": "Colinz Laboratories Hits New 52-Week Low at Rs. 36.11",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/colinz-laboratories-hits-new-52-week-low-at-rs-3611-3696966",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/ColinzLaborator_priceRelatedfactors_3696966.png",
        "date": "2025-11-13 09:58:38",
        "description": "Colinz Laboratories has reached a new 52-week low of Rs. 36.11, reflecting a year-to-date decline of 32.98%. Despite recent gains over three days, the company faces challenges such as weak long-term fundamentals and low return on equity, while the broader market shows mixed performance."
      },
      {
        "title": "Colinz Laboratories Hits New 52-Week Low at Rs. 37.4",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/colinz-laboratories-hits-new-52-week-low-at-rs-374-3689984",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/ColinzLaborator_priceRelatedfactors_3689984.png",
        "date": "2025-11-11 14:13:49",
        "description": "Colinz Laboratories has reached a new 52-week low, reflecting a significant downturn in its stock performance. The company has underperformed its sector and experienced a notable decline over the past year, with weak financial metrics contributing to its challenges in the market."
      }
    ],
    "total": 595,
    "sid": "621096",
    "stock_news_url": "https://www.marketsmojo.com/news/colinz-laboratories-621096"
  },
  "announcements": [
    {
      "caption": "Announcement under Regulation 30 (LODR)-Newspaper Publication",
      "datetime": "28-Jan-2026",
      "details": "Dear Sir As required under Regulation 47(3) of SEBI (LODR) Regulations 2015. Please find the attached News Paper Publication made towards our issued Quarterly Results for Dec-25. Kindly take the same on records. For Colinz Labs Ltd Director",
      "source": "BSE"
    },
    {
      "caption": "Board Meeting Outcome for Outcome Of The Board Meeting Under Regulation 30 And 33 Of SEBI (Listing Obligation And Disclosure Requirements) Regulations 2015.",
      "datetime": "24-Jan-2026",
      "details": "We would like to inform you that the Board of Directors of the Company at their meeting held today i.e. 24th January 2026 has inter alia considered and approved Unaudited Financial Results (as per IND-AS) for the Quarter and Nine Months Ended on 31st December 2025.",
      "source": "BSE"
    },
    {
      "caption": "Outcome Of The Board Meeting Under Regulation 30 And 33 Of SEBI (Listing Obligation And Disclosure Requirements) Regulations 2015.",
      "datetime": "24-Jan-2026",
      "details": "As required under Regulations 30 and 33 we are attaching herewith the our Quarterly Results as on Dec-2025. Kindly take the same on records. Directors",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "No <strong>Dividend</strong> history available",
      "data": []
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "No <strong>Splits</strong> history available",
      "data": []
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "No <strong>Bonus</strong> history available",
      "data": []
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

Colinz Laboratories Ltd Forms Golden Cross, Signalling Potential Bullish Breakout

2026-01-28 18:00:15

Colinz Laboratories Ltd has recently formed a Golden Cross, a significant technical indicator where the 50-day moving average (DMA) has crossed above the 200-day moving average. This development often signals a potential bullish breakout, indicating a possible trend reversal and a shift towards long-term upward momentum for the pharmaceutical and biotechnology company.

Read full news article

Are Colinz Laboratories Ltd latest results good or bad?

2026-01-25 19:11:24

Colinz Laboratories Ltd's latest financial results for Q3 FY26 reveal a complex operational landscape characterized by contrasting trends in revenue and profitability. The company reported net sales of ₹1.43 crores, reflecting a quarter-on-quarter increase of 2.88%. However, this modest growth is overshadowed by a significant decline in net profit, which fell to ₹0.08 crores, representing a 42.86% decrease from the previous quarter. The profit after tax (PAT) margin also saw a notable contraction, dropping to 5.59% from 10.07% in the prior quarter, indicating challenges in maintaining operational efficiency and cost management. While the operating margin improved slightly to 6.99%, it remains below previous levels, highlighting ongoing issues with profitability. Year-on-year comparisons further illustrate the company's struggles, as revenue decreased by 2.72% from ₹1.47 crores in Q3 FY25. This trend of d...

Read full news article

Colinz Laboratories Q3 FY26: Marginal Revenue Growth Masks Deeper Profitability Concerns

2026-01-24 21:31:19

Colinz Laboratories Ltd., a micro-cap pharmaceutical formulations manufacturer, reported a modest quarterly performance for Q3 FY26, with net profit declining 42.86% quarter-on-quarter to ₹0.08 crores from ₹0.14 crores in Q2 FY26. On a year-on-year basis, net profit increased 60.00% from ₹0.05 crores in Q3 FY25, though this comparison benefits from an exceptionally weak base quarter. With a market capitalisation of just ₹13.00 crores, the Mumbai-based company continues to struggle with scale and profitability consistency, as reflected in its current stock price of ₹46.20, down 47.91% from its 52-week high of ₹88.70.

Read full news article

Colinz Laboratories Ltd is Rated Strong Sell

2025-12-26 15:12:03

Colinz Laboratories Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 11 June 2025. However, the analysis and financial metrics presented here reflect the stock's current position as of 26 December 2025, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.

Read full news article

Why is Colinz Labs falling/rising?

2025-12-20 02:14:07

Recent Price Movement and Volatility

Colinz Laboratories has experienced a notable downturn over the past three days, with cumulative losses amounting to 11.44%. The stock opened sharply lower on 19-Dec, down 2%, and reached an intraday low of ₹44.41, representing a 14.6% decline from previous levels. Trading activity was marked by high volatility, with an intraday price range of ₹7.59 and a volatility measure of 7.86% based on weighted average price. Despite this, the weighted average price indicated that most volume was transacted near the lower end of the day’s range, signalling selling pressure.

Technical indicators reveal a mixed picture. The stock price remains above its 20-day, 50-day, and 100-day moving averages, suggesting some underlying support. However, it ...

Read full news article

Colinz Labs Sees Revision in Market Evaluation Amidst Challenging Financial Trends

2025-12-09 10:10:07

Colinz Labs, a microcap player in the Pharmaceuticals & Biotechnology sector, has experienced a revision in its market evaluation reflecting ongoing challenges in its financial and operational metrics. This development highlights shifts in the company’s quality, valuation, financial trends, and technical outlook, providing investors with a clearer understanding of its current standing within a competitive industry.

Read full news article

Why is Colinz Labs falling/rising?

2025-11-14 21:44:17

As of 14-Nov, Colinz Laboratories Ltd is experiencing a price increase, currently at 42.74, which reflects a rise of 0.94 or 2.25%. The stock has shown strong performance recently, gaining for four consecutive days and achieving a total return of 7.49% during this period. Additionally, it has outperformed its sector by 1.88%. In terms of returns compared to the benchmark, over the past week, the stock has increased by 2.91%, while the Sensex has risen by 1.62%. The stock's delivery volume has also seen a significant increase of 48.13% compared to the five-day average, indicating rising investor participation. However, it is important to note that there is no information available regarding any positive or negative factors that could further explain the stock's recent movement. Broader Market Context: In the short term, Colinz Laboratories Ltd has outperformed the Sensex, which suggests that investor sentim...

Read full news article

Colinz Laboratories Hits New 52-Week Low at Rs. 36.11

2025-11-13 09:58:38

Colinz Laboratories has reached a new 52-week low of Rs. 36.11, reflecting a year-to-date decline of 32.98%. Despite recent gains over three days, the company faces challenges such as weak long-term fundamentals and low return on equity, while the broader market shows mixed performance.

Read full news article

Colinz Laboratories Hits New 52-Week Low at Rs. 37.4

2025-11-11 14:13:49

Colinz Laboratories has reached a new 52-week low, reflecting a significant downturn in its stock performance. The company has underperformed its sector and experienced a notable decline over the past year, with weak financial metrics contributing to its challenges in the market.

Read full news article

View All News